Evaluation of the protective potential of a recombinant modified vaccinia virus Ankara (MVA) encoding rift valley fever virus (RVFV) glycoproteins in lambs

Evaluation of the protective potential of a recombinant modified vaccinia virus Ankara (MVA) encoding rift valley fever virus (RVFV) glycoproteins in lambs

Bibliographic Details
Main Authors:	Busquets, N, Lopez, E, Lorenzo, G, Abad, F, Galindo, I, Rivas, R, Solanes, D, Bensaid, A, Rodriguez, F, Gilbert, S, Domingo, M, Brun, A
Format:	Journal article
Published:	2011

Similar Items

Efficacy assessment of an MVA vectored Rift Valley Fever vaccine in lambs.
by: Busquets, N, et al.
Published: (2014)

Efficacy assessment of an MVA vectored Rift Valley Fever vaccine in lambs
by: Busquets, N, et al.
Published: (2014)

Diseño y construcción de vectores de transferencia para la obtención de virus vaccinia Ankara modificado (MVA) recombinantes Design and construction of transfer vectors in order to obtain recombinant modified vaccinia virus Ankara (MVA)
by: M. F. Ferrer, et al.
Published: (2007-09-01)

Modified Vaccinia Virus Ankara (MVA) as Production Platform for Vaccines against Influenza and Other Viral Respiratory Diseases
by: Arwen F. Altenburg, et al.
Published: (2014-07-01)

Diversity of cell death signaling pathways in macrophages upon infection with modified vaccinia virus Ankara (MVA)
by: Lioba Klaas, et al.
Published: (2021-10-01)

Recombination-mediated genetic engineering of a bacterial artificial chromosome clone of modified vaccinia virus Ankara (MVA).
by: Matthew G Cottingham, et al.
Published: (2008-02-01)

Correction: Recombination-Mediated Genetic Engineering of a Bacterial Artificial Chromosome Clone of Modified Vaccinia virus Ankara (MVA).
by: Matthew G. Cottingham, et al.
Published: (2011-01-01)

Recombination-mediated genetic engineering of a bacterial artificial chromosome clone of modified vaccinia virus Ankara (MVA).
by: Cottingham, M, et al.
Published: (2008)

Genome Sequencing of a Camelpox Vaccine Reveals Close Similarity to Modified <i>Vaccinia virus</i> Ankara (MVA)
by: Maurilia Marcacci, et al.
Published: (2020-07-01)

Correction: Recombination-Mediated Genetic Engineering of a Bacterial Artificial Chromosome Clone of Modified Vaccinia virus Ankara (MVA)
Published: (2011-01-01)

Induction of antibody responses to African horse sickness virus (AHSV) in ponies after vaccination with recombinant modified vaccinia Ankara (MVA).
by: Rachael Chiam, et al.
Published: (2009-06-01)

Zinc-finger antiviral protein (ZAP) is a restriction factor for replication of modified vaccinia virus Ankara (MVA) in human cells.
by: Chen Peng, et al.
Published: (2020-08-01)

Comparison of RT-qPCR and RT-ddPCR with Rift valley fever virus (RVFV) RNA
by: Changwoo Park, et al.
Published: (2023-02-01)

Can vaccinia virus be replaced by MVA virus for testing virucidal activity of chemical disinfectants?
by: Rapp Ingrid, et al.
Published: (2010-06-01)

Clinical development of Modified Vaccinia virus Ankara vaccines
by: Gilbert, S
Published: (2013)

Clinical development of Modified Vaccinia virus Ankara vaccines.
by: Gilbert, S
Published: (2013)

Lack of toxicity and persistence in the mouse associated with administration of candidate DNA- and modified vaccinia virus Ankara (MVA)-based HIV vaccines for Kenya.
by: Hanke, T, et al.
Published: (2002)

Safety and immunogenicity of IMVAMUNE®, a third-generation vaccine based on the modified vaccinia Ankara (MVA) strain
by: L. F. Stovba, et al.
Published: (2023-04-01)

MVA Vectored Vaccines Encoding Rift Valley Fever Virus Glycoproteins Protect Mice against Lethal Challenge in the Absence of Neutralizing Antibody Responses
by: Elena López-Gil, et al.
Published: (2020-02-01)

Innate immune sensing of modified vaccinia virus Ankara (MVA) is mediated by TLR2-TLR6, MDA-5 and the NALP3 inflammasome.
by: Julie Delaloye, et al.
Published: (2009-06-01)

Recombinant modified vaccinia virus Ankara expressing glycoprotein E2 of Chikungunya virus protects AG129 mice against lethal challenge.
by: Petra van den Doel, et al.
Published: (2014-09-01)

A modified vaccinia Ankara virus (MVA) vaccine expressing African horse sickness virus (AHSV) VP2 protects against AHSV challenge in an IFNAR -/- mouse model.
by: Javier Castillo-Olivares, et al.
Published: (2011-01-01)

Vaccination with a modified vaccinia virus Ankara (MVA)-vectored HIV-1 immunogen induces modest vector-specific T cell responses in human subjects.
by: Howles, S, et al.
Published: (2010)

Retraction: Innate Immune Sensing of Modified Vaccinia Virus Ankara (MVA) Is Mediated by TLR2-TLR6, MDA-5 and the NALP3 Inflammasome
by: The Editors
Published: (2022-01-01)

Cardiac Safety in Clinical Trials with Preventive HIV Vaccine Candidates Based on Modified Vaccinia Ankara (MVA)
by: Schmidt, C, et al.
Published: (2008)

A Genotype of Modified Vaccinia Ankara (MVA) that Facilitates Replication in Suspension Cultures in Chemically Defined Medium
by: Volker Sandig, et al.
Published: (2013-01-01)

Development of Modified Vaccinia Virus Ankara-Based Vaccines: Advantages and Applications
by: Olga Vladimirovna Orlova, et al.
Published: (2022-09-01)

Elements in the Development of a Production Process for Modified Vaccinia Virus Ankara
by: Volker Sandig, et al.
Published: (2013-11-01)

A single immunization with MVA expressing GnGc glycoproteins promotes epitope-specific CD8+-T cell activation and protects immune-competent mice against a lethal RVFV infection
by: López-Gil, E, et al.
Published: (2013)

Ty virus-like particles, DNA vaccines and Modified Vaccinia Virus Ankara; comparisons and combinations.
by: Gilbert, S, et al.
Published: (1999)

Modified Vaccinia Virus Ankara as a Viral Vector for Vaccine Candidates against Chikungunya Virus
by: Juan García-Arriaza, et al.
Published: (2021-08-01)

A single immunization with MVA expressing GnGc glycoproteins promotes epitope-specific CD8+-T cell activation and protects immune-competent mice against a lethal RVFV infection.
by: Elena López-Gil, et al.
Published: (2013-01-01)

Modified Vaccinia virus Ankara-based vaccines in the era of personalized immunotherapy of cancer
by: Kaïdre Bendjama, et al.
Published: (2017-09-01)

Hazard Characterization of Modified Vaccinia Virus Ankara Vector: What Are the Knowledge Gaps?
by: Malachy I. Okeke, et al.
Published: (2017-10-01)

Studies of a prophylactic HIV-1 vaccine candidate based on modified vaccinia virus Ankara (MVA) with and without DNA priming: effects of dosage and route on safety and immunogenicity.
by: Peters, B, et al.
Published: (2007)

Immunogenicity and Safety of Modified Vaccinia Ankara (MVA) Vaccine—A Systematic Review and Meta-Analysis of Randomized Controlled Trials
by: Lior Nave, et al.
Published: (2023-08-01)

Tracking the inter-epidemic activity of Rift Valley fever (RVFV) virus in RVF outbreak hotspots in Kenya: Determination of biotic and socio-economic drivers
by: R. Sang, et al.
Published: (2014-04-01)

Safety and immunogenicity of recombinant low-dosage HIV-1 A vaccine candidates vectored by plasmid pTHr DNA or modified vaccinia virus Ankara (MVA) in humans in East Africa.
by: Jaoko, W, et al.
Published: (2008)

Using the vaccinia virus MVA strain for developing recombinant vector vaccines against current arboviral infections
by: L. F. Stovba, et al.
Published: (2021-11-01)

Phase II trial of Modified Vaccinia Ankara (MVA) virus expressing 5T4 and high dose Interleukin-2 (IL-2) in patients with metastatic renal cell carcinoma
by: Mitcham Josephine, et al.
Published: (2009-01-01)